Venture Medical Invests in Plasmacure for Cold Plasma Wound Healing Tech

Venture Medical, LLC, a prominent figure in advanced wound care solutions, has recently finalized a strategic investment in Plasmacure B.V., a Dutch medical technology company known for its innovative PLASOMA cold plasma therapy aimed at enhancing complex wound healing. This investment marks a pivotal step in a €6 million Series A funding round, with contributions from Coöperatie VGZ, Noaber, Stichting Triade, and existing investors EIC Fund and OostNL. Furthering its commitment, Venture Medical is dedicating over $10 million to support PLASOMA's journey through regulatory approval, reimbursement processes, and expansion into the U.S. market.

The partnership highlights Venture Medical’s mission to empower healthcare providers by introducing groundbreaking technologies that improve patient outcomes and broaden access to cutting-edge care solutions. John Schroeder, CEO of Venture Medical, emphasized the significance of addressing chronic wounds, which greatly impact patients and burden healthcare systems. Schroeder views PLASOMA as a transformative technology that could redefine wound healing possibilities. By investing in Plasmacure, Venture Medical aims to facilitate the availability of innovative and accessible next-generation care for clinicians.

PLASOMA distinguishes itself as a unique wound healing system utilizing cold plasma delivered through a user-friendly pulser and specialized applicator, effectively generating plasma directly on the wound from room air. Cold plasma has exhibited strong antimicrobial properties while fostering tissue regeneration through various mechanisms. Recent clinical trials have shown PLASOMA therapy achieving 2.5 times the wound closure compared to current care standards.

For Venture Medical, this investment aligns with its broader commitment to providing healthcare providers with pioneering tools across biologics, diagnostics, durable medical equipment, and digital solutions. PLASOMA represents a scalable and scientifically supported option for treating diabetic foot ulcers, venous leg ulcers, pressure ulcers, and other difficult-to-heal wounds.

Schroeder highlighted the growing demand for effective wound healing solutions, driven by an aging population and increasing prevalence of chronic conditions. Through PLASOMA, Venture Medical is not only addressing wounds but also restoring access, independence, and dignity to patients who have lived without hope.

The funding aims to accelerate Plasmacure's global expansion while setting the stage for U.S. FDA clearance, payer access, and national distribution via Venture Medical’s extensive provider network. Bjorn Sprengers, CEO of Plasmacure, expressed motivation by the needs of millions living with hard-to-heal wounds and confidence in the company’s strong position to extend PLASOMA's reach to more patients worldwide.

Venture Medical, LLC, based in the U.S., specializes in advanced wound care services, functioning as a master distributor and digital solutions partner. The company equips clinicians with breakthrough biologics, diagnostics, and capital equipment to enhance patient outcomes across various care settings.

Plasmacure B.V., established in 2014 in the Netherlands, develops PLASOMA—a cold plasma therapy designed to accelerate healing in chronic wounds. The company strives to revolutionize wound care through technology that is safe, effective, and scalable.